In today’s recent session, 14.43 million shares of the Inhibikase Therapeutics Inc (NASDAQ:IKT) have been traded, and its beta is 1.33. Most recently the company’s share price was $1.60, and it changed around $0.41 or 34.45% from the last close, which brings the market valuation of the company to $11.94M. IKT at last check was trading at a discount to its 52-week high of $3.82, offering almost -138.75% off that amount. The share price’s 52-week low was $0.79, which indicates that the recent value has risen by an impressive 50.62% since then. We note from Inhibikase Therapeutics Inc’s average daily trading volume that its 10-day average is 13920.0 shares, with the 3-month average coming to 21.83K.
Inhibikase Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended IKT as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Inhibikase Therapeutics Inc is expected to report earnings per share of -0.67 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Inhibikase Therapeutics Inc (NASDAQ:IKT) trade information
Instantly IKT has been showing a green trend so far today with a performance of 34.45% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.9199 on recent trading dayincreased the stock’s daily price by 16.66%. The company’s shares are currently up 25.98% year-to-date, but still up 33.33% over the last five days. On the other hand, Inhibikase Therapeutics Inc (NASDAQ:IKT) is 19.40% up in the 30-day period. We can see from the shorts that 39655.0 shares have been sold at a short interest cover period of 1.71 day(s).
Inhibikase Therapeutics Inc (IKT) estimates and forecasts
Inhibikase Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -25.58 percent over the past six months and at a 22.97% annual growth rate that is well above the industry average of 19.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 22.10% in revenue this quarter, and will report a decrease of -7.80% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.31%.
IKT Dividends
Inhibikase Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-12.
Inhibikase Therapeutics Inc (NASDAQ:IKT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 12.02% of Inhibikase Therapeutics Inc shares, and 14.34% of them are in the hands of institutional investors. The stock currently has a share float of 16.30%.
